QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 jmp-securities-maintains-market-outperform-on-structure-therapeutics-lowers-price-target-to-86

JMP Securities analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers ...

 structure-therapeutics-q2-eps-018-beats-023-estimate

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate o...

 obesity-drugs-focused-stocks-tumble-on-wednesday---whats-going-on-with-eli-lilly-novo-nordisk-viking-therapeutics-structure-therapeutics

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 bmo-capital-maintains-outperform-on-structure-therapeutics-raises-price-target-to-100

BMO Capital analyst Evan David Seigerman maintains Structure Therapeutics (NASDAQ:GPCR) with a Outperform and raises the pri...

 reported-earlier-structure-therapeutics-prices-upsized-476m-public-offering-9066972-american-depositary-shares-at-5250ads

Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecu...

 structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforglipron-analyst-says

Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Canto...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION